Company News Archives

Company News

Podcast: Naseem Amin, Orphalan CEO, discusses Wilson’s Disease and the potential advancements in its treatments on DNA Today

DNA Today is a multi-award-winning podcast and radio show exploring how genetics impacts our health. Host/Producer Kira Dineen interviews leaders in genetics including genetic counsellors, researchers, physicians, and patient advocates…

adminFebruary 6, 2023

Company News

Dr. Naseem Amin, Chief Executive Officer at Orphalan, discusses the announcement of the FDA approval of Cuvrior™

Dr. Naseem Amin, Chief Executive Officer at Orphalan, discusses the announcement of the FDA approval of Cuvrior™ in this video: https://www.youtube.com/watch?v=Yu2WsUwtayE

adminMay 3, 2022

Company News Video

Top line results of CHELATE trial presented at International Liver Congress 2021. Top line Summary by Michael Schilsky, MD

adminJune 25, 2021

Company News

This morning, Dr Weiss presented our Phase 3 data at @EASL | The Home of Hepatology’s International Liver Congress 2021.

Friday 25 June Today we are excited to announce positive top-line data from our Phase 3 head-to-head trial of trientine tetrahydrochloride and d-penicillamine. This is the first trial of its…

adminJune 25, 2021

At Orphalan we identify, develop and provide access to innovative treatments for patients with rare diseases. The information available on this Website is for information purposes only.

We work in a highly-regulated industry with unique legal considerations. Medical and health information may be presented but the content we share is not intended to provide professional medical advice, diagnosis or treatment.

Always seek medical advice from qualified health care professional for any questions you may have regarding your medical condition.

To report an adverse event experience for any Orphalan product please contact us by writing to AdverseEventReporting@orphalan.com or calling direct: +356 2776 1718, or calling the local toll free telephone number listed under your country and choosing option 3.

Company News

Podcast: Naseem Amin, Orphalan CEO, discusses Wilson’s Disease and the potential advancements in its treatments on DNA Today

Dr. Naseem Amin, Chief Executive Officer at Orphalan, discusses the announcement of the FDA approval of Cuvrior™

Top line results of CHELATE trial presented at International Liver Congress 2021. Top line Summary by Michael Schilsky, MD

This morning, Dr Weiss presented our Phase 3 data at @EASL | The Home of Hepatology’s International Liver Congress 2021.

Global Headquarters

Legal

Useful Links